Get the Stockscreener App
1.78
3.26%
-0.06
After Hours:
1.77
-0.01
-0.56%
Nls Pharmaceutics Ltd stock is traded at $1.78, with a volume of 40,955.
It is down -3.26% in the last 24 hours and down -17.97% over the past month.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
See More
Previous Close:
$1.84
Open:
$1.85
24h Volume:
40,955
Relative Volume:
0.02
Market Cap:
$7.41M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-3.56
EPS:
-0.5
Net Cash Flow:
$-13.51M
1W Performance:
-6.32%
1M Performance:
-17.97%
6M Performance:
-69.33%
1Y Performance:
-87.56%
1-Day Range:
$1.77
$1.85
1-Week Range:
$1.72
$1.9212
52-Week Range:
$1.71
$18.39
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Compare NLSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
1.78 | 7.41M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - ACCESS Newswire
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire
NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com
Can NLS Pharmaceutics' Orexin Agonist Treat More Than Just Sleep Disorders? New Data Says Yes - StockTitan
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - PR Newswire
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire
NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq
Is NLSP’s price to cash per share ratio a concern for investors? - US Post News
NLS Pharmaceutics Ltd’s Shares Reel: -37.16% Quarterly Revenue Decline Amid 6.35M Market Cap - The InvestChronicle
NLS Pharmaceutics Ltd (NLSP) Shares Rise Despite Market Challenges - The News Heater
Stock market today: Patriot National Bancorp +46.21%, NLS Pharmaceutics +37.43% among top gainers in early trading - Business Upturn
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - GuruFocus.com
NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph
NLS Pharmaceutics and Kadimastem Announce Merger to Innovate Diabetes Treatment - TipRanks
Are NLS Pharmaceutics Ltd’shares a good deal? - US Post News
Navigating NLSP Stock: NLS Pharmaceutics Ltd Journey - The InvestChronicle
NLS Pharmaceutics Ltd (NASDAQ: NLSP) Defies Bearish Expectations and Displays Strong Future Potential - Marketing Sentinel
NLS and Kadimastem move forward with merger plans - MSN
Israeli startup Kadimastem to merge With NLS Pharmaceutics - MSN
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference - ACCESS Newswire
NLS and Kadimastem move forward with merger plans By Investing.com - Investing.com Canada
NLS Gains on Deal with Kardimastem - Baystreet.ca
Kadimastem Shareholders Greenlight Merger with NLS - Sleep Review
NLS Pharmaceutics Amends Merger Agreement with Kadimastem - TipRanks
Stock market news: Reborn Coffee +65.76%, NLS Pharmaceutics +30.81% among top gainers during mid day trading - Business Upturn
NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise - Marketscreener.com
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - ACCESS Newswire
Kadimastem Shareholders Approve Merger with NLS Pharmaceutics - TipRanks
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics -January 31, 2025 at 07:31 am EST - Marketscreener.com
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - Nasdaq
NLS Pharmaceutics and Kadimastem Move Forward with Merger to Create Nasdaq-Traded Biotechnology Company - HPBL
NLS Abstracts Showcase Narcolepsy and Diabetes-Related Sleep Research - Sleep Review
NLS Pharmaceutics and Kadimastem Merger & Financing Update – Market - HPBL
NLS Pharmaceutics Submits Research Abstracts to ASCP 2025 - TipRanks
Revolutionary Fentanyl Addiction Treatment Among 3 Major Breakthroughs from NLS Pharma - StockTitan
NLS Pharmaceutics Ltd (NLSP) Has A Bright Growth Prospects For 2025 - Marketing Sentinel
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
NLS Pharmaceutics Launches Preclinical Program for Fentanyl Dependence Treatment - TipRanks
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com
Game-Changing Drug Could End Fentanyl Epidemic: NLS Pharma's Bold Move - StockTitan
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - ACCESS Newswire
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - ACCESS Newswire
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - ACCESS Newswire
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing - ACCESS Newswire
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform - ACCESS Newswire
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - ACCESS Newswire
NLS Pharmaceutics Announces Company Update on Strategic Partnerships - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - ACCESS Newswire
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):